The new draft guidance also contains FDA recommendations for CGMP requirements on preventing cross-contamination of these products, including the separate manufacturing of non-penicillin beta-lactam antibacterial drugs from other drug manufacturing processes, as well as alternate recommendations when complete separation of manufacturing is not possible.
Public comment is open until 23 August 2022.
RF Regulatory Focus: News
> Do not hesitate, we look forward to your feedback!
Write a comment on this news.